NCT05450887: Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis |
|
|
| Completed | 3 | 108 | RoW | Obeticholic Acid Tablets（OCA）, UDCA, Placebo | Nanjing Chia-tai Tianqing Pharmaceutical | Primary Biliary Cholangitis | 03/24 | 04/24 | | |
NCT05193916: A Phase II Clinical Trial of Chiglitazar for NASH |
|
|
| Completed | 2 | 104 | RoW | chiglitazar sodium tablets, Bilessglu®, CS-038, Carfloglitazar, Placebo, simulant of chiglitazar | Chipscreen Biosciences, Ltd. | NASH | 01/24 | 01/24 | | |
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) |
|
|
| Recruiting | 2 | 280 | Europe, Canada, Japan, US, RoW | Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo | GlaxoSmithKline | Chronic Hepatitis B Virus Infection, Hepatitis B | 10/27 | 10/27 | | |
